ATE455791T1 - T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon - Google Patents

T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon

Info

Publication number
ATE455791T1
ATE455791T1 AT06709221T AT06709221T ATE455791T1 AT E455791 T1 ATE455791 T1 AT E455791T1 AT 06709221 T AT06709221 T AT 06709221T AT 06709221 T AT06709221 T AT 06709221T AT E455791 T1 ATE455791 T1 AT E455791T1
Authority
AT
Austria
Prior art keywords
individuals
majority
epstein
epitopes
applications
Prior art date
Application number
AT06709221T
Other languages
German (de)
English (en)
Inventor
Veronique Pancre
Claude Auriault
Stephane Depil
Bernard Maillere
Olivier Morales
Gaetan Munier
Original Assignee
Centre Nat Rech Scient
Commissariat Energie Atomique
Univ Lille Ii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Commissariat Energie Atomique, Univ Lille Ii filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE455791T1 publication Critical patent/ATE455791T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06709221T 2005-02-07 2006-02-02 T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon ATE455791T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0501198A FR2881746B1 (fr) 2005-02-07 2005-02-07 Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications
PCT/FR2006/000229 WO2006082313A2 (fr) 2005-02-07 2006-02-02 Epitopes t cd4+ des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus db la population caucasienne et leurs applications

Publications (1)

Publication Number Publication Date
ATE455791T1 true ATE455791T1 (de) 2010-02-15

Family

ID=35116028

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06709221T ATE455791T1 (de) 2005-02-07 2006-02-02 T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon

Country Status (8)

Country Link
US (1) US20090130134A1 (cg-RX-API-DMAC10.html)
EP (1) EP1861418B1 (cg-RX-API-DMAC10.html)
JP (1) JP4972562B2 (cg-RX-API-DMAC10.html)
AT (1) ATE455791T1 (cg-RX-API-DMAC10.html)
CA (1) CA2596929C (cg-RX-API-DMAC10.html)
DE (1) DE602006011859D1 (cg-RX-API-DMAC10.html)
FR (1) FR2881746B1 (cg-RX-API-DMAC10.html)
WO (1) WO2006082313A2 (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011699A1 (en) * 1993-10-29 1995-05-04 The Trustees Of Boston University Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
AU774861B2 (en) * 1998-02-11 2004-07-08 Douglas V Faller Compositions and methods for the treatment of cystic fibrosis
FR2830940B1 (fr) 2001-10-17 2007-06-15 Commissariat Energie Atomique Procede de selection de ligands d'hla-dp4 et ses applications
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
BRPI0815395A2 (pt) 2007-08-15 2015-02-10 Circassia Ltd Composição, vetor, produto, formulação farmacêutica, me´todo in vitro para determinar se as células t reconhecem um polipeptídeo, e, método in vitro para determinar se um indivíduo se encontra ou está em risco de uma condição.
WO2010105112A1 (en) * 2009-03-11 2010-09-16 Hemaquest Pharmaceuticals, Inc. Detection of short-chain fatty acids in biological samples
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
WO2011072086A1 (en) 2009-12-08 2011-06-16 Hemaquest Pharmaceuticals, Inc. Methods and low dose regimens for treating red blood cell disorders
US20110245154A1 (en) 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
CA3132353A1 (en) 2012-05-08 2013-11-14 The Johns Hopkins University Methods and compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes to treat cancer
CN105555756B (zh) 2013-06-28 2018-12-07 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
CA2971677A1 (en) 2014-12-23 2016-06-30 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
TW201735952A (zh) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
EP4650005A3 (en) 2016-07-15 2026-01-28 Viracta Subsidiary, Inc. Histone deacetylase inhibitors for use in immunotherapy
CN110809716B (zh) 2017-02-12 2023-07-07 百欧恩泰美国公司 基于hla的方法和组合物及其用途
KR20200101394A (ko) 2017-12-20 2020-08-27 글락소스미스클라인 바이오로지칼즈 에스.에이. 엡스타인-바 바이러스 항원 구축물
CA3124457A1 (en) * 2018-12-21 2020-06-25 Biontech Us Inc. Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
TWI853940B (zh) 2019-05-31 2024-09-01 美商維拉克塔股份有限公司 以組蛋白去乙醯酶抑制劑治療病毒相關癌症之方法
IL295241B1 (en) * 2020-02-10 2026-06-01 Univ Johns Hopkins Cancer immunotherapy using allogeneic and tumor-specific T-cell and CD4 cell transfusions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040157780A1 (en) * 1993-11-29 2004-08-12 Epimmune Inc. CTL inducing peptides from c-erb2 (HER-2/neu)
WO1996002563A1 (en) * 1994-07-13 1996-02-01 Cornell Research Foundation, Inc. Epstein-barr virus nuclear antigen 1 protein and its expression and recovery
US20020141995A1 (en) * 1997-06-10 2002-10-03 Irvin Charles G. Method for treatment of inflammatory disease
CA2392456A1 (en) * 1999-11-24 2001-05-31 Oklahoma Medical Research Foundation Assays and therapies for latent viral infection
EP1229043A1 (en) * 2001-01-30 2002-08-07 Cyto-Barr B.V. Peptides derived from Epstein Barr virus (EBV) proteins LMP1, LMP2 and BARF1 antibody reagents reactive therewith
GB0214528D0 (en) * 2002-06-24 2002-08-07 Univ Aberdeen Materials and methods for induction of immune tolerance
AU2003246485A1 (en) * 2002-07-16 2004-02-02 Affinium Pharmaceuticals, Inc. Interactions of the epstein-barr virus protein ebna1, and uses thereof
WO2004041849A1 (en) * 2002-11-07 2004-05-21 The Council Of The Queensland Institute Of Medical Research Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
US20040141995A1 (en) * 2002-12-10 2004-07-22 Rongfu Wang MHC class I-restricted and MHC class II-restricted EBNA1 peptides

Also Published As

Publication number Publication date
US20090130134A1 (en) 2009-05-21
FR2881746B1 (fr) 2007-04-13
JP2008529486A (ja) 2008-08-07
JP4972562B2 (ja) 2012-07-11
DE602006011859D1 (de) 2010-03-11
WO2006082313A2 (fr) 2006-08-10
WO2006082313A3 (fr) 2007-01-11
FR2881746A1 (fr) 2006-08-11
EP1861418A2 (fr) 2007-12-05
CA2596929A1 (fr) 2006-08-10
EP1861418B1 (fr) 2010-01-20
CA2596929C (fr) 2015-12-29

Similar Documents

Publication Publication Date Title
DE602006011859D1 (de) T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon
EA201070271A1 (ru) Пептиды для получения вакцины
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
CY1119284T1 (el) ΣΩΜΑΤΙΔΙΑ ΠΑΡΟΜΟΙΑ ΜΕ ΙΟ ΓΛΥΚΟ-ΠΡΩΤΕΪΝΗΣ ΛΥΣΣΑΣ (VLPs)
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
EA201390806A1 (ru) Конструкция пептидного каркаса
CA2821268C (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
DOP2013000029A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
MX341842B (es) Virus de la influenza capaces de infectar canidos y usos de los mismos.
MA44665B1 (fr) Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques
MX2013007918A (es) Peptidos inmunogenicos monomericos y multimericos.
EA201170353A1 (ru) Антитела против гепатита с и их применение
WO2009042895A3 (en) Reagents for inducing an immune response
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
WO2014160747A3 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
HK1207871A1 (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
EA201300132A1 (ru) Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич
TW200726479A (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
EP4448497A4 (en) TETRAHYDROPYRIDAZINES, COMPOSITIONS COMPRISING THEM AND THEIR USES
PT1951300E (pt) Modificação do equilíbrio de th1/th2 em vacinas da influenza fragmentadas com adjuvantes
WO2013006050A9 (en) Peptides inducing or enhancing an immune response against prostate-specific membrane protein (psma)
MX2009005026A (es) Anticuerpos anti-tsg101 y sus usos para tratamiento de infecciones virales.
TW200725839A (en) Stacked wafer or die packaging with enhanced thermal and device performance

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties